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Sebaceous Skin Lesions as Clues to 
Hereditary Non-Polyposis Colorectal 
Cancer
Henry T. Lynch1, Ramon M. Fusaro1–3 and Patrick M. Lynch4
Cutaneous lesions consonant with Muir–Torre syndrome strongly suggest 
hereditary non-polyposis colorectal cancer (HNPCC). Ponti et al. discuss the 
importance of combining molecular genetic features of the sebaceous neo-
plasms, including microsatellite instability and immunohistochemistry, with 
family history, to determine the likelihood of HNPCC. Proof of diagnosis is 
identification of one of the mismatch repair germline mutations.
Journal of Investigative Dermatology (2006) 126, 2158–2159. doi:10.1038/sj.jid.5700534
The rarely occurring Muir–Torre syn-
drome (MTS) is a cancer-associated 
genodermatosis characterized by seba-
ceous adenomas, sebaceous carcino-
mas, and multiple keratoacanthomas in 
the presence of visceral cancers integral 
to hereditary non-polyposis colorectal 
cancer (HNPCC), also known as the 
Lynch syndrome. Muir et al. (1967) and 
Torre (1968) were the first to describe 
MTS, although they gave no mention 
of the presence or absence of a fam-
ily history. Subsequent reports of MTS 
involved patients with the above mani-
festations, but family histories were not 
routinely investigated.
Because of our interest in the pattern 
and natural history of multiple primary 
cancers identified in some of these pub-
lished case reports, including carcinoma 
of the colorectum and endometrium and 
other HNPCC tumors, then known as 
the “cancer family syndrome,” we con-
tacted several of these authors to request 
additional information about their cases, 
specifically, whether any of their data 
were consistent with HNPCC. One of 
the authors, a dermatopathologist, kind-
ly advised us about his patient with MTS 
cutaneous signs and visceral cancer 
who, after considerable discussion, had 
stated that she was a member of a very 
large extended family, namely, “Family 
G of Warthin,” which we were studying. 
This family has been under investigation 
for more than 100 years (Douglas et al., 
2005; Lynch and Krush, 1971; Warthin, 
1913). As far as we are aware, this report 
provided the first description of MTS in 
HNPCC (Lynch et al., 1981).
For more than 20 years, sebaceous 
skin tumors and keratoacanthomas 
have been known to be characteristic, 
albeit uncommon, features of HNPCC. 
Since the discovery that germline muta-
tions in members of the mismatch repair 
(MMR) family of genes are responsible 
for HNPCC, a variety of related find-
ings have made the central role of fam-
ily history less critical to the clinical 
diagnosis of HNPCC. Important among 
these has been the recognition that 
the vast majority of tumors in HNPCC 
patients show evidence of microsatellite 
instability (MSI). In turn, MSI has been 
found to correlate very strongly with 
immunohistochemical (IHC) abnor-
malities, specifically loss of staining in 
tumors of those proteins corresponding 
to specific MMR genes. Initially, most of 
these correlations, both MSI and IHC, 
were identified in colorectal cancers. 
More recently it has been observed 
that many of the associated tumors also 
show MSI and loss of expression with 
MMR IHC staining. When the family 
history (for example, Amsterdam I or II 
Criteria, or Bethesda Guidelines; see 
Supplementary Table S1), clinical pic-
ture (early age at onset, right colon pre-
dominance), or histologic features (poor 
differentiation, extracellular mucin, 
tumor-infiltrating lymphocytes) are sug-
gestive of HNPCC, performance of MSI 
testing or IHC is warranted. When infor-
mative, MSI and IHC can lead to effec-
tive germline mutation testing.
Ponti et al. (2006, this issue) describe 
a series of HNPCC families in which a 
small number of cases, about 1%, had 
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characteristic MTS skin lesions. This is 
probably very conservative, as it was 
not shown that all evaluated subjects 
were, in fact, mutation carriers. In addi-
tion, it was noted that meticulous skin 
examinations were not performed on 
all subjects. Nevertheless, the key point 
was that in all of the characteristic skin 
lesions, MSI and IHC were informa-
tive. In another report by these authors 
(Ponti et al., 2005), an algorithm was 
described by which sebaceous tumors 
would be subjected to MSI and IHC. 
Informative cases would then undergo 
mutational testing after family-history 
characterization. Subjects with micro-
satellite-stable tumors but with positive 
family history would be screened clini-
cally for visceral tumors.
Importantly, a question to consider is 
whether, given the relative infrequency 
of such lesions, routine testing for MSI 
and IHC may be warranted for any 
sebaceous tumor or keratoacanthoma. 
If the issue were testing of colorectal 
cancer, a very common visceral malig-
nancy, the answer would be that univer-
sal testing for MSI and IHC is not war-
ranted. Population studies have shown 
that although about 15% of colorectal 
cancers show MSI, most do so because 
of somatically acquired hypermethyl-
ation of the MLH1 promoter and thus 
are not indicative of HNPCC (Hampel 
et al., 2005). So in this setting, MSI and 
IHC point to the presence of HNPCC 
only when some additional clinical 
information is present (for example, 
when the Bethesda Guidelines are 
met; see Supplementary Table S1). But 
sebaceous skin tumors are sufficiently 
uncommon that it is unlikely that events 
such as hypermethylation of the MLH1 
promoter would lead to a high rate of 
“false positives.”
A second question deals with the 
uti lity of detailed family-history evalua-
tion in such patients. We have already 
mentioned that when the Bethesda 
Guidelines are met in a patient with 
colorectal cancer, the positive predic-
tive value of MSI and IHC testing is 
much improved. How much the addi-
tion of clinical information such as 
positive family or personal history of 
visceral malignancy helps in patients 
with sebaceous skin tumors is less clear. 
Obviously a positive family history is 
helpful, but this really begs the question 
of whether any family history is needed 
to support MSI and IHC in the patient 
with sebaceous skin tumors.
Perhaps an analogy would prove 
helpful. Familial adenomatous pol-
yposis (FAP), including its attenuated 
variant (AFAP), and HNPCC carry an 
increased risk of duodenal adenomas 
and cancer, tumors that are otherwise 
quite rare in the general population. If 
an endoscopist identifies a duodenal 
adenoma or cancer in a patient under-
going upper gastrointestinal endoscopy 
for any reason (for example, dyspep-
sia or heartburn), then colonoscopy is 
generally recommended, on the small 
chance that FAP, AFAP, or HNPCC may 
be present. The yield is generally not 
great in this setting. However, because 
so few patients have duodenal neopla-
sia, and because our threshold for rec-
ommending colonoscopy for any risk 
factor is low, the approach is not hard 
to rationalize. So the argument follows 
this line of reasoning for patients with 
sebaceous lesions: (1) sebaceous tumors 
are rare; (2) they are commonly associ-
ated with HNPCC; (3) MSI and IHC are 
informative at least 10% of the time, a 
reasonable cutoff for deciding to follow 
through with the appropriate laboratory 
assessment; (4) whether or not MSI and 
IHC are done or are informative, colo-
noscopy screening is warranted.
Lack of awareness of the MTS cuta-
neous findings may be the most impor-
tant reason for underreporting of MTS. 
Ponti et al. (2006) clearly state that 
underestimation of MTS is probably 
due to the scarce importance assigned 
to research on the subject, with cor-
responding inattention to sebaceous 
gland tumors in personal and fam-
ily anamnestic surveys. These authors 
appropriately wish to include seba-
ceous carcinomas among tumors that 
should be tested for MSI (Umar et al., 
2004). They contend that these rare 
lesions should be carefully examined 
through these molecular tests even 
when they appear in individuals with-
out evidence of visceral malignancy, a 
contention that we also support.
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